Other languages Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
24.52 ^USD	-2.15%		+7.54%	-24.51%

May. 02	Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating	MT
May. 01	Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Corcept Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01
Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial	Apr. 29
Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	Apr. 22
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	Apr. 15
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome	Apr. 01
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing	Mar. 21
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16
Sector Update: Health Care Stocks Gain Pre-Bell Friday	Feb. 16
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance; Shares Gain Pre-Bell	Feb. 16
Sector Update: Health Care	Feb. 16
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance	Feb. 15
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024	Feb. 15
Corcept Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
Corcept Therapeutics Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15
Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial	Feb. 15
Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology	Jan. 29
Corcept Therapeutics Sees 31% Increase in Q4 Revenue, Issues 2024 Revenue Guidance	Jan. 08
Corcept Therapeutics Incorporated announces an Equity Buyback for $200 million worth of its shares.	Jan. 08
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024	Jan. 08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Other languages

Filters